Alia Therapeutics is developing next-generation gene-editing therapies that utilize precise genome editing techniques to target and correct mutations responsible for rare genetic diseases. By focusing on the efficacy and durability of these treatments, the company aims to provide long-lasting cures that address the root causes of genetic disorders.
Funding
$6.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many genetic diseases lack effective treatments that address the underlying genetic mutations. Traditional approaches often fall short in providing long-lasting cures, especially for highly heterogeneous genetic diseases with limited therapeutic options. Existing gene editing technologies may also struggle to access certain genomic sites or lack the specificity needed for safe and precise modifications.
Solution
Alia Therapeutics is developing gene-editing therapies using novel CRISPR enzymes to target and correct mutations responsible for genetic diseases. Their approach focuses on discovering and utilizing a diverse portfolio of CRISPR enzymes, including Cas9 and Cas12 systems, to expand the range of targetable genomic sites and increase the precision of genetic modifications. By employing customized approaches and proprietary pipelines like the PAM Prediction Algorithm and on-target directed EVOlution platform, Alia aims to unlock new therapeutic windows and ensure the safety of their gene editing technologies. Their lead program targets Autosomal Dominant Retinitis Pigmentosa (adRP) using a mutation-independent editing strategy delivered via a single AAV vector.
Target Audience
Alia Therapeutics targets patients with genetic diseases, particularly those with limited therapeutic options, and seeks partnerships with biotech and industry leaders for co-development and licensing initiatives.
Features
- Proprietary pipelines for discovering novel nucleases tailored for therapeutic applications
- Diverse portfolio of CRISPR enzymes, including Cas9 and Cas12 systems
- PAM Prediction Algorithm for identifying new targetable genomic sites
- On-target directed EVOlution platform for increasing the precision of genetic modifications
- Mutation-independent editing strategies for addressing heterogeneous genetic diseases
- Single AAV vector delivery for lead program targeting Autosomal Dominant Retinitis Pigmentosa (adRP)